Genmab A/S shares surged the most in more than six years after its experimental ovarian cancer treatment exceeded analyst expectations in a late-stage trial, boosting confidence in the Danish drugmaker’s pipeline.
Genmab A/S shares surged the most in more than six years after its experimental ovarian cancer treatment exceeded analyst expectations in a late-stage trial, boosting confidence in the Danish drugmaker’s pipeline.
<iframe src="https://statesidedaily.com/embed/cluster/99cdca5e249c484886f00f8b36a79d9526d67eb4" width="100%" height="320" style="border:0;max-width:680px" loading="lazy" title="Genmab Soars as Cancer Drug Impresses in a Late-Stage Trial"></iframe>
